Author name: Ying Mak

Technology for successful decentralised clinical trials

The landscape of clinical trials is undergoing a profound transformation, one that holds the promise of faster drug development, increased patient participation, and improved data quality.  At the forefront of this revolution stands the concept of Decentralised Clinical Trials (DCTs), a game-changing approach that is reshaping the way we conduct clinical research. In this blog […]

Technology for successful decentralised clinical trials Read More »

Success Factors for Remote and Hybrid Decentralised Trials from Site, Technology and Service Provider Perspectives with a Focus on the RADIAL Study from Trials@Home

Success Factors for Remote and Hybrid Decentralised Trials From Site, Technology and Service Provider Perspectives with a Focus on the RADIAL Study from Trials@Home About this webinar Thursday 16th November 2023 10:00-11:00 EST | 15:00-16:00 GMT Platform: Zoom Webinars Amidst the enthusiasm surrounding the advantages and efficiencies promised by Decentralised Clinical Trials (DCTs), encompassing remote

Success Factors for Remote and Hybrid Decentralised Trials from Site, Technology and Service Provider Perspectives with a Focus on the RADIAL Study from Trials@Home Read More »

Launch of automated quality assurance for clinical trials

News Back to resource centre 24 October 2023 Launch of automated quality assurance for clinical trials Cambridge Cognition (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce the launch today of AQUA, the Company’s automated quality assurance solution for central nervous system (“CNS”) clinical trials that is powered

Launch of automated quality assurance for clinical trials Read More »

Why don’t we trust people’s lived-experience of fatigue?

Fatigue is the sort of subjective phenomenological experience that has plagued philosophers and neuroscientists for centuries. For those with lived experience, fatigue can be debilitating, and patients can be left feeling ignored and maligned. Despite over 17 million people across Europe1, reporting symptoms of Long Covid, with fatigue being the most common symptom, there is

Why don’t we trust people’s lived-experience of fatigue? Read More »

Speech based biomarkers for monitoring progressive changes in Alzheimer’s disease

A speech based composite which tracks change in AD over time was recently developed and piloted through a collaboration between Winterlight Labs and Genentech.

Speech is a rich source of clinical information when assessing and monitoring Alzheimer’s Disease. Natural language processing technologies, like those developed by Winterlight Labs, can objectively quantify speech and enable its use as a novel endpoint in drug development.

Speech based biomarkers for monitoring progressive changes in Alzheimer’s disease Read More »

Highlights from AAIC 2023

The headline from this year’s AAIC in Amsterdam is undoubtedly the announcement of the results of TRAILBLAZER-ALZ-2, a phase 3 trial of Eli Lilly’s new drug Donanemab with 1,800 participants. Donanemab is an antibody-based drug that works by breaking down already-formed amyloid plaques that build up in Alzheimer’s disease (AD), rather than interfering with their production.

Highlights from AAIC 2023 Read More »

Frontiers in Neurology | Revolutionising the detection of cognitive impairment in multiple sclerosis with technology

Publications & posters Back to resource centre 11 January 2023 Revolutionising the detection of cognitive impairment in multiple sclerosis with technology Cognitive dysfunction is a leading cause of disability in multiple sclerosis (MS), yet practical restraints mean it often goes unassessed in routine clinical care. Promising new research, published in Frontiers in Neurology, suggests the Cambridge Neuropsychological Test Automated Battery

Frontiers in Neurology | Revolutionising the detection of cognitive impairment in multiple sclerosis with technology Read More »

Frontiers in Psychiatry | Using affective cognition to enhance precision psychiatry

Publications & posters Back to resource centre 11 January 2023 Using affective cognition to enhance precision psychiatry Precision psychiatry is a promising new approach that seeks to improve outcomes in highly heterogeneous clinical populations. Frontiers in Psychiatry recently published an interesting opinion piece on “Using Affective Cognition to Enhance Precision Psychiatry” 1 by Dr Jack Cotter, Clinical Science Team Lead at Cambridge

Frontiers in Psychiatry | Using affective cognition to enhance precision psychiatry Read More »

CANTAB Mobile: experience of use of a digital memory screening tool in primary care

Publications & posters Back to resource centre 11 January 2023 CANTAB Mobile: experience of use of a digital memory screening tool in primary care Early identification of memory complaints in clinical settings can aid identification of deficits, or reassurance, and can support care planning and management. CANTAB Mobile combines a sensitive touchscreen memory test, with a depression screen to differentiate

CANTAB Mobile: experience of use of a digital memory screening tool in primary care Read More »

Evaluating the challenges and benefits of fully decentralized and hybrid clinical trials

Back to resource centre Evaluating the challenges and benefits of fully decentralized and hybrid clinical trials A pan-European interventional study to enrol Diabetes Mellitus (DM) patientsThe RADIAL concept study aims to generate delivering scientific evidence and data on the benefits and challenges of running a DCT Clinpal is the core platform for this in a 3-arm (conventional, hybrid, remote) clinical trial

Evaluating the challenges and benefits of fully decentralized and hybrid clinical trials Read More »

Scroll to Top